BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34450232)

  • 1. Signal transducer and activator of transcription 3 signaling in tumor immune evasion.
    Zhang L; Kuca K; You L; Zhao Y; Musilek K; Nepovimova E; Wu Q; Wu W; Adam V
    Pharmacol Ther; 2022 Feb; 230():107969. PubMed ID: 34450232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
    Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
    Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxynivalenol upregulates hypoxia-inducible factor-1α to promote an "immune evasion" process by activating STAT3 signaling.
    Zhang L; Wang X; Nepovimova E; Wu Q; Wu W; Kuca K
    Food Chem Toxicol; 2023 Sep; 179():113975. PubMed ID: 37517547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hypoxia-inducible factor 1 in tumor immune evasion.
    You L; Wu W; Wang X; Fang L; Adam V; Nepovimova E; Wu Q; Kuca K
    Med Res Rev; 2021 May; 41(3):1622-1643. PubMed ID: 33305856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells.
    Niu G; Briggs J; Deng J; Ma Y; Lee H; Kortylewski M; Kujawski M; Kay H; Cress WD; Jove R; Yu H
    Mol Cancer Res; 2008 Jul; 6(7):1099-105. PubMed ID: 18644974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance.
    Witalisz-Siepracka A; Klein K; Zdársky B; Stoiber D
    Front Immunol; 2022; 13():947568. PubMed ID: 35865518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
    Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
    J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 10. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
    Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
    Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
    [No Abstract]   [Full Text] [Related]  

  • 11. Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways.
    Xiang Z; Zhou Z; Song S; Li J; Ji J; Yan R; Wang J; Cai W; Hu W; Zang L; Zhu Z; Zhang Z; Li M; Yu Y
    Oncogene; 2021 Aug; 40(31):5002-5012. PubMed ID: 34175886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.
    Teng R; Wang Y; Lv N; Zhang D; Williamson RA; Lei L; Chen P; Lei L; Wang B; Fu J; Liu X; He A; O'Dwyer M; Hu J
    J Immunol Res; 2020; 2020():4598476. PubMed ID: 33123602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A perylene derivative regulates HIF-1α and Stat3 signaling pathways.
    Chen H; Guan Y; Yuan G; Zhang Q; Jing N
    Bioorg Med Chem; 2014 Feb; 22(4):1496-505. PubMed ID: 24485121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRIM-19 repressed hypoxia-induced invasion and EMT of colorectal cancer by repressing autophagy through inactivation of STAT3/HIF-1α signaling axis.
    Zhang J; Chu D; Kawamura T; Tanaka K; He S
    J Cell Physiol; 2019 Aug; 234(8):12800-12808. PubMed ID: 30537081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
    Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
    Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
    [No Abstract]   [Full Text] [Related]  

  • 17. IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung.
    Jing B; Wang T; Sun B; Xu J; Xu D; Liao Y; Song H; Guo W; Li K; Hu M; Zhang S; Ling J; Kuang Y; Zhang T; Zhou BP; Yao F; Deng J
    Cancer Res; 2020 Feb; 80(4):784-797. PubMed ID: 31848193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
    Tang Q; Jiang J; Liu J
    Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TCM formula comprising Sophorae Flos and Lonicerae Japonicae Flos alters compositions of immune cells and molecules of the STAT3 pathway in melanoma microenvironment.
    Liu YX; Bai JX; Li T; Fu XQ; Guo H; Zhu PL; Chan YC; Chou JY; Yin CL; Li JK; Wang YP; Chen YJ; Yu ZL
    Pharmacol Res; 2019 Apr; 142():115-126. PubMed ID: 30797070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.